awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q38631019-803F332A-D8EC-420D-B15E-B1377DAA33BD
Q38631019-803F332A-D8EC-420D-B15E-B1377DAA33BD
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38631019-803F332A-D8EC-420D-B15E-B1377DAA33BD
Treatment of ALK-rearranged non-small cell lung cancer: A review of the landscape and approach to emerging patterns of treatment resistance in the Australian context.
P2860
Q38631019-803F332A-D8EC-420D-B15E-B1377DAA33BD
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38631019-803F332A-D8EC-420D-B15E-B1377DAA33BD
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
11cdd779bf7b26abb1ec7a7f2d1fd30111ae04a7
P2860
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.